Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
December 9, 2008

Axiogenesis’ Cor.At Cells to Be Integrated with Roche’s xCELLigence System

  • Roche and Axiogenesis entered into an agreement for the development and distribution for Axiogenesis’ Cor.At® 100% pure cardiomyocytes as a part of the xCELLigence cell-analysis system. Cell systems based on the Cor.At technology customized for the xCELLigence platform will be marketed.

    The xCELLigence System is designed for a applications spanning from short-term kinetic analysis like measuring effects on G-protein coupled receptors to assays for cell proliferation and cytoxicity. The Cor.At cells are not only quality-controlled, storable, and available under GMP-conditions but resemble a physiologically normal phenotype of either neonate or adult heart. Coupling the Cor.At cells and the xCELLigence system enables research studies to focus on long-term life behavior of cardiac cells in vitro, according to the companies.